Editor's note channel feed

#JPM24 re­flec­tions: No pol­i­tics, no Mi­a­mi and where the mon­ey is in biotech right now

Last year

What we’re do­ing dif­fer­ent­ly at JP Mor­gan this year

Last year

Did I ever tell you the one about the drunk­en biotech awards pro­gram I host­ed at a Chica­go bar?

Last year
Bioregnum

Why End­points is bring­ing a new fo­cus to our man­u­fac­tur­ing cov­er­age

Last year
Manufacturing

Ex­pand­ing the End­points news­room over­seas, a spe­cial projects hire and our new lead for events

Last year

How you ac­cess End­points News is chang­ing

3 years ago

I'm host­ing some (live!) pan­els and fire­sides for our up­com­ing Boston biotech sum­mit. Please join me there

3 years ago

An­nounc­ing three ex­cit­ing jour­nal­ists who are join­ing the End­points news­room

3 years ago

Who are the young bio­phar­ma lead­ers mak­ing their mark in the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

3 years ago

A small change in your in­box each morn­ing

3 years ago

What's next at End­points: a big­ger, more am­bi­tious news­room

3 years ago

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

3 years ago

Who are the women blaz­ing trails in bio­phar­ma R&D? Nom­i­nate them for End­points' 2022 spe­cial re­port

3 years ago

End­points ed­i­tors se­lect the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard da­ta on AI and can ac­cel­er­at­ed ap­proval re­main in­tact?

4 years ago
Special

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

4 years ago

End­points News wants to know: Is your com­pa­ny man­dat­ing Covid-19 vac­cines?

4 years ago
Pharma

Fol­low biotechs go­ing pub­lic with the End­points News IPO Track­er

5 years ago

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

5 years ago

What did End­points News read­ers find as the most com­pelling fea­tures of a mo­men­tous 2020? Here are the top 10

5 years ago

Our 3rd an­nu­al UK bio­phar­ma event tops this week — on Zoom — with José Basel­ga, top biotech CEOs and a look at the glob­al fi­nan­cial scene

5 years ago

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for End­points' spe­cial re­port

5 years ago
People

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

6 years ago

The End­points 100: No­var­tis gets 'poor' grade on da­ta scan­dal, Ned Sharp­less is­n't a 'wow' and that Cana­da drug im­por­ta­tion plan is a non­starter

6 years ago

That feel­ing you get when you hit the fin­ish line, and then set new goals

7 years ago
Bioregnum
Opinion
First page Previous page 123 Next page Last page
A service from the Financial Times